Skip to main content
. 1999 Apr;19(4):2913–2920. doi: 10.1128/mcb.19.4.2913

FIG. 2.

FIG. 2

(A) Activation of a Stat1-responsive reporter by the Stat1-ER chimera in Stat1-deficient U3A cells. U3A cells were transfected with an empty expression vector (pcDNA3.1) or an expression vector for either Stat1-ER or wtStat1 plus the Stat1-responsive reporter IRF-1x4-tk-luc and a β-Gal control plasmid. After transfection, cells were treated with estrogen (E2; 20 h), tamoxifen (Tam; 20 h) or IFN-γ (5 h), lysed, and assayed for luciferase and β-Gal activities. The normalized responses were determined by dividing relative light units measured in a luciferase assay with the β-Gal activity in the same lysate, and the fold induction (induced/untreated) was calculated by using the averaged normalized responses from three independent experiments. (B) HepG2 cells were transfected with the IRF-1x4-tk-luc reporter and an expression vector for Stat1-ER (circles) or the estrogen-responsive ERE-tk-luc reporter and an expression vector for wild-type ER (diamonds). Both sets included a β-Gal control plasmid. Cells were treated with the indicated concentrations of estrogen (20 h), lysed, and assayed for luciferase and β-Gal activities. The normalized responses are expressed as a percentage of the maximal normalized response for each treatment and are presented as the mean of three independent experiments. (C) Effect of Stat1 Ser727 Ala mutation on transcriptional activity of Stat1-ER and wtStat1 in Stat1-deficient U3A cells. (D) DNA sequence specificity of the Stat1-ER chimera. Stat1-deficient U3A cells were transfected with an expression vector for Stat1-ER and either a Stat1-responsive reporter (IRF-1x4-tk-luc) or a Stat6-selective reporter (mGɛx4-pGL2) together with a β-Gal control plasmid. Treatments and calculations were performed as described for panel A. un, untreated; Tam, tamoxifen treated.

HHS Vulnerability Disclosure